Neurotoxicity of chemotherapy;Complications neurologiques des chimiotherapies

Revue de Medecine Interne

Volumn 20, Issue 10, 1999, Pages 902-911

  Lebrun, C ^a   Frenay, M ^b   Lanteri Minet, M ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cancer; Chemotherapy; Neurotoxicity; Quality of life

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; IFOSFAMIDE; ISAXONINE; MERCAPTAMINE; TAXANE DERIVATIVE; VINCA ALKALOID; ANTINEOPLASTIC AGENT;

CANCER THERAPY; DOSE RESPONSE; MYASTHENIA; MYOPATHY; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; PARALYSIS; PERIODIC PARALYSIS; QUALITY OF LIFE; REVIEW; CHEMICALLY INDUCED DISORDER; HUMAN; NEOPLASM; NEUROLOGIC DISEASE;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; QUALITY OF LIFE;

EID: 0033213459     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)80095-8     Document Type: Article

References (48)

1. Frenay M, Lebrun C, Mousseau M, Chatel M. Principes généraux de la chimiothérapie des tumeurs neuroépithéliale primitives (TNEP) de l'adulte. Encycl Méd Chir (Elsevier, Paris). Neurologie, 17-305-A10. 1995 ; 12 p.
2. Dubas F, Serre I. Complications vasculaires cérébrales des cancers. Revue Neurol 1992 ; 148 : 663-71.
3. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998 ; 245 : 695-708.
4. Hildebrand J. Peripheral neuropathy. In: Hildebrand J, ed. Neurological Adverse Reactions to Anticancer Drugs. Berlin: Spring-Verlag; 1990. p. 90-9.
5. Cappelaere P, Dubois F. Complications neurologiques de la chimiothérapie. In: Tumeurs du Système Nerveux et de ses Enveloppes. Paris : Flammarion ; 1989. p. 802-10.
6. Pace A, Bove L, Nistico C, Ranuzzi M, Innocenti P, Pietrangeli A, et al. Vinorelbine neurotoxicity: Clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996 ; 61 : 409-11.
7. Lebrun C, Chichmanian RM, Chatel M, Frenay M. Recurrent bowel occlusion with oral ondansetron: A previously unknown adverse event. Ann Oncol 1997 ; 8 : 919-20.
8. McDonald DR. Neurotoxicity of chemotherapeutic agents. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore: Williams and Wilkins; 1992. p. 666-79.
9. Ongerbœr de Visser BW, Tiessens G. Polyneuropathy induced by cisplatin. Prog Exp Tumor Res 1985 ; 29 : 190-96.
10. Lindeman G, Kefford R, Stuart-Harris R. Cisplatin neurotoxicity [letter]. N Engl J Med 1990 ; 323 : 64.
11. Pannetiere FJ. Cisplatinium neurotoxicity: An analysis based on 3 SWOG studies [letter]. Proc Am Assoc Cancer Res 1981 ; 22 : 163.
12. Elderson A, Van der Hoop GR, Haanstra W, Neijt JP, Gipsen WH, Jennekens FGI. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 1989 ; 93 : 167-74.
13. Eeles R, Tait DM, Peckman HJ. Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep 1986 ; 70 : 905-7.
14. Onetto N, Dougan M, Hellmann S, et al. Safety profile. In: Paclitaxel in Cancer Treatment. William McGuire E, Rowinsky, eds. New York: 1995. p. 135-8.
15. Gelmon K. The taxoids: Paclitaxel and docetaxel. Lancet 1994 ; 344 : 1267-72.
16. Hilkens PHE, Verweij J, Stoter G, Vecht CJ, Van Putten WLJ, Van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996 ; 46 : 104-8.
17. Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989 ; 39 : 368-73.
18. Chaudhry V, Rowinsky EK, Sartorius RN, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 1994 ; 35 : 304-11.
19. Küpfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994 ; 343 : 763-4.
20. Jackson DW, Wells HB, Atkins JN, Zekan PJ, White DR, Richards F, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988 ; 84 : 1016-22.
21. Cavaletti G, Cascinu S, Venturino P, Tedeschi M, Tredici G. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res 1996 ; 16 : 3149-59.
22. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy: Risk factors, prognosis, and protection by WR-2721. Cancer 1988 ; 61 : 2192-5.
23. Van der Hoop GR, Vecht CJ, Van der Buurg MEL, Elderson A, Boogerd W, Heimans JJ, Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 1990 ; 322 : 89-94.
24. Posner JB. Neurologic Complications of Cancer. Philadelphia: Davis; 1995.
25. Guthrie TH, Gynther L. Acute deafness: A complication of high-dose cisplatin. Arch Otolaryngol 1985 ; 111 : 344-5.
26. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990 ; 322 : 126-7.
27. Defer G, Fauchon F, Schaison M, Chiras J, Brunet P. Visual toxicity following intra-arterial chemotherapy with hydroxyethyl-CNU in patients with malignant gliomas. Neuroradiology 1991 ; 33 : 432-7.
28. Wilson WB, Perez GM, Kleinschmidt De Master BK. Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. Cancer 1987 ; 59 : 901-7.
29. Weiss HD, Walker MD, Wiernick PH. Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 1974 ; 291 : 127-33.
30. Kastru PO, Diener HC. Granulocyte-stimulating factor filgastrim and molgramostrim induced recurring encephalopathy and focal status epilepticus. J Neurol 1997 ; 244 : 274-5.
31. Peyrade F, Lebrun C, de Jaurequiberry JP, Taillan B, Jaubert D, Dujardin P. Perte de connaissance au cours d'un traitement par G-CSF. Rev Méd Interne 1997 ; 18 : 822-3.
32. Frenay M, Francois E, Fleming R, Namer M. Short-term and long-term sequelae of chemotherapy for testicular cancer. In: Giulani, Santi, Boccardo, Pescatore, eds. New Trends in Diagnosis and Treatment of Testicular Tumors (vol. 2). Munchen: 1992. p. 273-82.
33. Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination therapy for germ-cell tumors of the testis. Ann Intern Med 1986 ; 105 : 48-51.
34. Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986 ; 4 : 1845-50.
35. Dimaggio JR, Brown R, Baile WF, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994 ; 73 : 1509-14.
36. Burger PC, Kamenar E, Schold SC, Fay JW, Phillips GL, Herzig GP. Encephalopathy following high-dose BCNU therapy. Cancer 1981 ; 48 : 1318-27.
37. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel. Semin Oncol 1993 ; 20 : 1-15.
38. Walz R, Muxfeldt Bianchin M, Kliemann F. Transient encephalopathy after taxol infusion. Neurology 1997 ; 49 : 1188-9.
39. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997 ; 15 : 833-9.
40. Honnorat J. Anticorps antineuronaux et syndromes neurologiques paranéoplasiques. La Lettre du Neurologue 1997 ; 2 : 49-53.
41. Brashear A, Siemers E. Focal dystonia after chemotherapy: A case series. J Neurooncol 1997 ; 34 : 163-7.
42. Baker WJ, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991 ; 9 : 679-93.
43. Kleinschmidt-Demasters BK. Intracarotid BCNU leucoencephalopathy. Cancer 1986 ; 57 : 1276-80.
44. Delattre JY, Ameri A, Albuquerque L, Poisson M. Complications cérébrales tardives de la radiothérapie. Ann Med Int 1995 ; 145 : 125-32.
45. Pumar JM, Arrojo L, Seoane C, Garcia R, Castineira JA, Vidal J. Magnetic resonance signal alterations of the brain in asymptomatic patients treated with high-dose cisplatin for ovarian carcinoma. Eur J Cancer 1994 ; 30 : 721.
46. Reni M, Ferreri AJM, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of critical review of the literature. Ann Oncol 1997 ; 8 : 227-34.
47. Van Dam F, Schagen SB, Muller MJ, Boogerd W, Wall E, Droogleever Fortuyn MA, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998 ; 90 : 210-8.
48. Crosley CJ, Rorke LB, Evans A, Nigro M. Central nervous system lesions in childhood leukemia. Neurology 1978 ; 28 : 678-85.